on Zomedica Corp. (NASDAQ:ZOM)
Zomedica Partners with Boehringer Ingelheim for Equine Diagnostics
Zomedica Corp. has announced a strategic collaboration with Boehringer Ingelheim Animal Health USA Inc. The partnership aims to enhance diagnostic testing for equine endocrine disorders using Zomedica's TRUFORMA platform. This collaboration is set to integrate TRUFORMA into Boehringer's idPPID program, designed to detect and manage pituitary pars intermedia dysfunction (PPID) in horses.
Through this agreement, veterinarians will have access to rapid endocrine testing, facilitating prompt diagnosis and treatment of PPID. Boehringer Ingelheim will support the initiative by reimbursing participating veterinarians for tests conducted using the TRUFORMA platform and through laboratory analysis at Cornell University.
This initiative involves placing TRUFORMA analyzers at no cost in veterinary practices, which are expected to boost the adoption and installed base of Zomedica’s platform. PPID is a common disorder in aging horses, affecting up to 25% of those over 15 years old. The collaboration aims to empower veterinarians to offer improved care for affected horses.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Zomedica Corp. news